Bridgeway Capital Management, LLC Corcept Therapeutics Inc Transaction History

Bridgeway Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$17.1 - $23.34 $324,900 - $443,460	-19,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$19.97 - $24.43 $63,904 - $78,176	3,200 Added 20.25%	19,000 $418,000
Q4 2020 Feb 16, 2021	SELL	$16.78 - $27.3 $26,848 - $43,680	-1,600 Reduced 9.2%	15,800 $413,000
Q3 2020 Nov 16, 2020	BUY	$12.46 - $19.98 $216,804 - $347,652	17,400 New	17,400 $303,000
Q2 2019 Aug 14, 2019	SELL	$9.78 - $12.76 $445,967 - $581,856	-45,600 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$10.03 - $15.71 $158,474 - $248,218	-15,800 Reduced 25.73%	45,600 $535,000
Q4 2018 Feb 14, 2019	BUY	$11.29 - $17.19 $343,216 - $522,576	30,400 Added 98.06%	61,400 $820,000
Q1 2018 May 15, 2018	SELL	$14.59 - $25.5 $77,327 - $135,150	-5,300 Reduced 14.6%	31,000 $510,000
Q4 2017 Feb 14, 2018	SELL	$15.77 - $20.72 $23,655 - $31,080	-1,500 Reduced 3.97%	36,300 $656,000
Q3 2017 Nov 14, 2017	BUY	$12.3 - $19.3 $464,940 - $729,540	37,800	37,800 $730,000

347

86.6M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $6.3B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.